alzheon.com
Alzheon Publishes New Analyses from Phase 3 Studies Showing Clinical Benefit of Tramiprosate in Alzheimer’s Patients Who Are Carriers of APOE4, the Major Genetic Risk Factor in up to 65 Percent of Alzheimer’s Patients
Data published in The Journal of the Prevention of Alzheimer’s Disease is the first report to associate efficacy of an amyloid-targeted drug with the number of APOE4 alleles Results enable a novel ‘precision medicine’ approach in Alzheimer’s drug development: Pivotal studies of ALZ-801, an oral prodrug of tramiprosate, to target AD patients who